Caduceus Mercurius
Holofractale de l'hypervérité
- Inscrit
- 14 Juil 2007
- Messages
- 9 628
Rick Doblin from the Multidisciplinarian Association for Psychedelic Studies recently wrote that:
"On Saturday, February 23, 2008, after more than a decade of hard work, Dr. John Halpern conducted the first experimental session in his study of MDMA-assisted psychotherapy in twelve subjects with treatment-resistant anxiety associated with advanced-stage cancer. Dr. Halpern is also conducting a major five-year NIDA-funded study into the neurocognitive risks of heavy use of Ecstasy, enhancing his ability to balance the risks and benefits of MDMA."
"This experimental session was the first time in 42 years that a psychedelic was administered to a research subject at Harvard Medical School. Dr. Walter Pahnke, who conducted the classic Good Friday experiment in 1962, reported on the conclusion of his psilocybin research at Harvard in an unpublished paper written in 1966."
"The renaissance in psychedelic research has begun. It is now time to prove what we have been claiming for decades, that psychedelic-assisted psychotherapy can be beneficial to some patients in carefully controlled clinical settings. The promising results from MAPS' US MDMA/PTSD research, and the start of Dr. Halpern's MDMA/cancer anxiety study, suggest that the eventual approval of psychedelic psychotherapy is becoming more than a dream."
More positive news has come from the The Cottonwood Research Foundation, scientific inquiry into the nature of consciousness. Rick Strassman (author of DMT, Spirit Molecule writes:
"We have already started our first research project. Our vice-president Dr. Steven Barker at Louisiana State University is developing a new ultra-sensitive method of measuring naturally occurring DMT and related compounds in the body. By doing so, we will be able to compare normal levels with those found in naturally occurring highly altered states and clinical conditions."
To read Rick Strassman's letter, go here.
"On Saturday, February 23, 2008, after more than a decade of hard work, Dr. John Halpern conducted the first experimental session in his study of MDMA-assisted psychotherapy in twelve subjects with treatment-resistant anxiety associated with advanced-stage cancer. Dr. Halpern is also conducting a major five-year NIDA-funded study into the neurocognitive risks of heavy use of Ecstasy, enhancing his ability to balance the risks and benefits of MDMA."
"This experimental session was the first time in 42 years that a psychedelic was administered to a research subject at Harvard Medical School. Dr. Walter Pahnke, who conducted the classic Good Friday experiment in 1962, reported on the conclusion of his psilocybin research at Harvard in an unpublished paper written in 1966."
"The renaissance in psychedelic research has begun. It is now time to prove what we have been claiming for decades, that psychedelic-assisted psychotherapy can be beneficial to some patients in carefully controlled clinical settings. The promising results from MAPS' US MDMA/PTSD research, and the start of Dr. Halpern's MDMA/cancer anxiety study, suggest that the eventual approval of psychedelic psychotherapy is becoming more than a dream."
More positive news has come from the The Cottonwood Research Foundation, scientific inquiry into the nature of consciousness. Rick Strassman (author of DMT, Spirit Molecule writes:
"We have already started our first research project. Our vice-president Dr. Steven Barker at Louisiana State University is developing a new ultra-sensitive method of measuring naturally occurring DMT and related compounds in the body. By doing so, we will be able to compare normal levels with those found in naturally occurring highly altered states and clinical conditions."
To read Rick Strassman's letter, go here.
